Zoetis is experiencing its worst stock decline ever, down 70% from its peak, due to weaker U.S. veterinary clinic visits and increased competition in key animal health segments. Despite aggressive competitor promotions, Zoetis maintains strong profitability with 35%-37% EBIT margins by using targeted rebates instead of cutting base prices. Trading at a low 12x P/E and offering a 7%+ free cash flow yield, the stock presents a margin of safety with a fair value estimate of $100.06. The company also provides a near 3% dividend yield and has $1.3 billion in share buyback capacity, supporting downside protection while short-term challenges persist.
Zoetis reported mixed earnings for Q2 and lowered its future guidance, reflecting challenges in U.S. pet-related sales. However, strong performance in other business segments helps balance the impact. Despite near-term difficulties, the overall risk/...
Zoetis (ZTS), a global leader in animal health products, now trades at a forward price-to-earnings ratio of 12 and offers a nearly 3% dividend yield after a prolonged price decline. Despite facing competition, weaker U.S. companion animal sales, and ...
